# Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

> **NCT04343755** · PHASE2 · TERMINATED · sponsor: **Hackensack Meridian Health** · enrollment: 52 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Convalescent Plasma

## Key facts

- **NCT ID:** NCT04343755
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-09
- **Primary completion:** 2023-04-26
- **Final completion:** 2023-04-26
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Lack of eligible patients due to change in standard therapy
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04343755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04343755, "Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04343755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*